Taking CAR-T Therapy to the Next Level is Part 2 of 3 of our most recent CAR-T series. The dialogue is focused on moving from autologous to allogeneic approaches and from blood based cancer therapy to treating solid tumors. The article also features a couple programs our panelists are actively working on that could change the outlook of CAR-T.
- Bill Farley, VP of Business and Corporate Development, Sorrento Therapeutics
- Anil Goyal, Chief Business Officer, MimiVax
- Michael Catelani, Chief Operating and Financial Officer, Anixa Biosciences
Subscribe to Kineticos to receive weekly emails containing insightful content.